Key result
Withdrawing antiplatelet therapy before surgery increases the risk of MI, stent thrombosis, or death 5 to 10 times, whereas aspirin and clopidogrel increase surgical hemorrhage risk by 20% and 50%.
Why the study?
Does the continuation of antiplatelet therapy affect the balance of thrombotic and hemorrhagic risks in patients undergoing urological surgery?
Does the continuation of antiplatelet therapy affect the balance of thrombotic and hemorrhagic risks in patients undergoing urological surgery?
In patients with prior MI or stents undergoing urological surgery, the thrombotic risk of stopping antiplatelet therapy generally exceeds the bleeding risk of continuing it, necessitating individualized multidisciplinary planning.
No takes yet. Share an insight, caveat, or question.
Supports individualized multidisciplinary planning for antiplatelet management in urological surgery; leaves open prospective validation of risk thresholds.
Eberli et al. (2010) conducted a review in Patients on dual antiplatelet therapy after myocardial infarction, cerebrovascular event or coronary stent implantation. Antiplatelet therapy withdrawal vs. Continuation of antiplatelet therapy was evaluated. Withdrawing antiplatelet therapy before surgery increases the risk of MI, stent thrombosis, or death 5 to 10 times, whereas aspirin and clopidogrel increase surgical hemorrhage risk by 20% and 50%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: